



7. References Related to Specific Instruments to Measure Peripheral Neuropathy

- Ajani, J.A., Welch, S.R., Raber, M.N., Fields, W.S., & Krakoff, I.H. (1990). Comprehensive criteria for assessing therapy-induced toxicity. *Cancer Investigation, 8*, 147–159.
- Almadrones, L., McGuire, D., Walczak, J., Florio, C., & Chungqiao, T. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. *Oncology Nursing Forum, 31*, 615–623. “ONS Member Access” link to <http://www.ons.org/publications/journals/ONF>
- Brundage, M.D., Pater, J.L., & Zee, B. (1993). Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. *Journal of the National Cancer Institute, 85*, 1138–1148.
- Calhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T., & Cella, D. (2003). Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. *International Journal of Gynecological Cancer, 13*, 741-8.
- Calhoun, E.A., Fishman, D.A., Roland, P.Y., Lurain, J.R., Chang, C.-H., & Cella, D. (2000). Validity and selective sensitivity of the FACT/GOG-Ntx. *Proceedings of the American Society of Clinical Oncology, 19*, 446a.
- Cavaletti, G., Bogliun, G., Marzorati, L., Zincone, A., Piatti, M., Colombo, N., et al. (2003). Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. *Neurology, 61*, 1297–1300.
- Cella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M.A. (2003). Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane). *Cancer, 98*, 822-31.
- Miller, A.B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981). Reporting results of cancer treatment. *Cancer, 47*, 207-214.
- National Cancer Institute. (2003). *Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0*. U.S. Department of Health and Human Services: National Cancer Institute: Bethesda.
- Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T, et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. *American Journal of Clinical Oncology, 5*, 49–55.